Status and phase
Conditions
Treatments
About
15 stable patients diagnosed with schizophrenia take 100 mg of VLT-015 once a day, 200 mg of VLT-015 once a day and 200 mg of VLT-015 on two consecutive days with an interval of 24 hours between doses. PK parameters are measured, tolerability and safety of the product are evaluated.
Full description
At stage 1, 15 stable patients diagnosed with schizophrenia take 1 tablet of VLT-015 (100 mg) followed by blood sampling to measure the level of the active substance and its main metabolite within 72 hours. After that patients have 3 days washout period.
At the second stage, the same 15 patients take two 100 mg tablets of VLT-015 (200 mg) followed by blood sampling to measure the level of the active substance and its main metabolite within 72 hours. Then patients have the same 3 days washout period.
At stage 3, the same patients take 2 tablets of VLT-015 (200 mg) consecutively for 2 days with 24-hours interval followed by blood sampling to measure the level of the active substance and its main metabolite within 96 hours.
PK parameters are measured, tolerability and safety of the product are evaluated.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Criteria determining the state of remission:
the sum of points of the Positive and Negative Symptom Scale (PANSS) according to positive Marder factor is less than 22 points,
each item score of the positive Marder factor (delusions, hallucinatory behavior, grandiosity, suspicion, stereotyped thinking, somatic anxiety, unusual thought content, decreased criticism) less than 4 points
Exclusion criteria
The presence of contraindications to the use of VLT-015:
Patients requiring medication or other concomitant therapies listed in the unacceptable concomitant therapy section;
The presence of prostatic hyperplasia or glaucoma in patients;
Diseases of the bone marrow in history;
Active tuberculosis, cystic fibrosis, systemic connective tissue diseases, oncological processes of any localization;
Severe, decompensated or unstable somatic diseases (any diseases or conditions that threaten the patient's life or worsen the prognosis patient, and also make it impossible to conduct a clinical trial);
Alcoholism and drug addiction at the present time, or in history;
Lack of patient willingness to cooperate, non-compliance of the patient;
Participation of the patient in any other clinical study in the last 30 days;
Patients planning to stay in the hospital during the study period for reasons other than the purposes of this clinical trial.
Primary purpose
Allocation
Interventional model
Masking
15 participants in 1 patient group
Loading...
Central trial contact
Max E Zapolski; Margarita A Morozova, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal